Results 221 to 230 of about 22,486 (258)
Some of the next articles are maybe not open access.
Genetic effects of hydralazine
Mutation Research/Genetic Toxicology, 1979Hydralazine and its acetone condensation product (ACP) were found to induce base-pair substitution mutations in the Salmonella/microsomal activation test system and to display genetic toxicity in the PolA+/A- test system. Incubation with a rat-liver microsomal fraction did not affect the genetic toxicity of either compound.
Jean-Paul Thenot +4 more
openaire +3 more sources
Hydralazine‐associated Glomerulonephritis
Acta Medica Scandinavica, 1985ABSTRACT. Nine patients (6 men, 3 women) with rapidly progressive glomerulonephritis developing during hydralazine therapy were seen. Early cessation of hydralazine treatment resulted in improvement in seven patients, while continued hydralazine treatment resulted in permanent renal insufficiency in two.
Christian Svalander +2 more
openaire +3 more sources
Journal of Pharmaceutical Sciences, 1989
The pharmacokinetics of hydralazine acetone hydrazone (HAH), which is a metabolite of hydralazine (HP), was investigated after iv administration to rats. Plasma concentrations of HAH, HP, and hydralazine pyruvic acid hydrazone (HPH) were simultaneously determined by a specific HPLC method.
Taro Ogiso +2 more
openaire +3 more sources
The pharmacokinetics of hydralazine acetone hydrazone (HAH), which is a metabolite of hydralazine (HP), was investigated after iv administration to rats. Plasma concentrations of HAH, HP, and hydralazine pyruvic acid hydrazone (HPH) were simultaneously determined by a specific HPLC method.
Taro Ogiso +2 more
openaire +3 more sources
Demonstration of anti-hydralazine antibody in hydralazine inducedLupus erythematosus
Experientia, 1963La presence d'un facteur anti-hydralazine, probablement un anticorps, a ete demontree par l'emploi d'une technique d'hemagglutination dans le serum d'un malade qui manifestait des symptomes de lupus erythemateux apres un long traitement avec de l'hydralazine.
H. Friedman, W. I. Heine
openaire +3 more sources
Clinical Pharmacokinetics of Hydralazine
Clinical Pharmacokinetics, 1982Hydralazine is one of the most frequently prescribed drugs for the treatment of moderate to severe hypertension. In addition, it is being used increasingly for the treatment of congestive heart failure when more traditional approaches fail. Although hydralazine has been in clinical use for 30 years, there is insufficient information concerning dose ...
J. L. McNay +10 more
openaire +2 more sources
European Journal of Clinical Pharmacology, 1976
The bioavailability of orally administered hydralazine was assessed in 4 healthy subjects after separate administration of a single oral or intravenous dose (0.3 mg-kg-1). Comparison of the areas under the serum concentration-time curves showed that 26-55% of the oral dose was available to the systemic circulation as unchanged drug.
openaire +2 more sources
The bioavailability of orally administered hydralazine was assessed in 4 healthy subjects after separate administration of a single oral or intravenous dose (0.3 mg-kg-1). Comparison of the areas under the serum concentration-time curves showed that 26-55% of the oral dose was available to the systemic circulation as unchanged drug.
openaire +2 more sources
Hydralazine elimination in man
Clinical Pharmacology & Therapeutics, 1973The metabolism of hydralazine has been studied in a series of experiments. The hydralazine plasma half‐life values in volunteers ranged from 2.2 to 7.8 hours in rapid acetylators and from 2.0 to 5.8 hours in slow acetylators. Plasma concentrations following intravenous administration were similar in slow and rapid acetylators, indicating similar ...
C. T. Bello +3 more
openaire +2 more sources
Hydralazine for essential hypertension
Cochrane Database of Systematic Reviews, 2011Hypertension is associated with an increased risk of stroke, myocardial infarction and congestive heart failure. Hydralazine is a direct-acting vasodilator which has been used for the treatment of hypertension since the 1950's. Although it has largely been replaced by newer antihypertensive drugs with more acceptable tolerability profiles, hydralazine ...
Michael R Kandler +4 more
openaire +3 more sources
Kinetics of hydralazine elimination
Clinical Pharmacology & Therapeutics, 1977Hydralazine was given orally in single doses of 10, 25, and 50 mg to 2 slow‐acetylating subjects, while 2 rapid‐acetylating subjects also received 100‐ and 150‐mg doses on different occasions. Administration of the 50‐mg dose to the subjects who were slow acetylators and the 150‐mg dose to those who were rapid acetylators caused a disproportionately ...
openaire +2 more sources
Polymorphic acetylation of hydralazine
Clinical Pharmacology and Therapeutics, 1980The acetylation of hydralazine has been studied in hypertensive patients undergoing maintenance therapy with the drug. The patients were acetylator phenotyped with sulfamethazine. Using gas-liquid chromatography and high-pressure liquid chromatography, hydralazine and two of its acetylated metabolites, methyltriazolophthalazine (MTP) and 3 ...
J. A. Timbrell +2 more
openaire +3 more sources